News | Breast Density | April 06, 2017

Colorado Enacts Dense Breast Tissue Reporting Bill

Beginning Oct. 1, 2017, mammography facilities will be required to notify patients if they have dense fibroglandular breast tissue, warn them of increased cancer risk

Colorado, fibroglandular breast density, reporting bill, mammography, breast cancer

April 6, 2017 — Colorado Gov. John Hickenlooper signed the Dense Breast Tissue Reporting Bill (SB17-142) on April 6, adding to the growing list of density reporting laws across the country. The signing makes Colorado the 29th state to enact some form of legislation requiring mammography facilities to notify patients about the impact of fibroglandular breast density on cancer detection and risk.

The language of SB17-142 requires mammography providers to include a notification in the report provided to the patient if the patient is found to have dense fibroglandular breast tissue. The notice must also inform the patient that while common, dense breast tissue can make it more difficult to evaluate the results of the mammogram and it is associated with an increased risk of breast cancer.

The bill was introduced in the Colorado Legislature by Sen. Angela Williams and sponsored in the House by Rep. Jessie Danielson.  The Colorado Breast Density Coalition actively advocated for the law.

“This is a victory for Colorado women,” said Williams.  "Now all women in Colorado will have the same information as their doctors."  

Danielson added, "This law encourages patients to discuss with healthcare providers screening options that are personalized to a patient with dense breast tissue. It is one solution to increase the early detection of breast cancer."

The law is effective on Oct. 1, 2017.  Currently, New Mexico, Iowa and Kentucky have breast density reporting bills awaiting governors' action.

For more information on dense breast tissue, read the article "Mammographic Breast Density — What It Means."

For more information: www.areyoudense.org

Related Content

Right mediolateral oblique (MLO) mammograms for different women with the same breast thickness but varying breast density.

Right mediolateral oblique (MLO) mammograms for different women with the same breast thickness but varying breast density.

News | Breast Imaging | July 30, 2021
July 30, 2021 — Volpara Health, a global health technology software leader providing an integrated breast care platfo
Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed an agreement with Invitae Corporation, a leader in medical genetics, to bring Invitae's genetic testing services to Volpara's customers in the United States. 
News | Breast Imaging | July 29, 2021
July 29, 2021 — Volpara Health, a global health technology software leader providing an...
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...
Volpara now holds 98 granted patents across 27 countries
News | Breast Imaging | July 16, 2021
July 16, 2021 — Volpara has recently been granted another patent by the...
According to ARRS’ American Journal of Roentgenology (AJR), return to routine screening for BI-RADS 3 lesions on supplemental automated whole-breast US (ABUS) substantially reduces the recall rate, while being unlikely to result in adverse outcome

Normal right mediolateral oblique (A) and craniocarudal (B) view screening mammograms demonstrate density C breasts. Coronal (C), transverse (D), and reconstructed lateral (E) views from supplemental automatic breast ultrasound (ABUS) demonstrates 7 mm circumscribed slightly hypoechoic circumscribed lesion at 11 o’clock position in right breast. Lesion was classified as BI-RADS 3. Patient has undergone yearly mammograms for 4 years following the ABUS examination with no breast cancer diagnosis.

News | Breast Imaging | July 16, 2021
July 16, 2021 —...
Interviews with the 1,000 at-risk patients also led to some interesting conclusions, Fine said. Even in the early days of 3D mammography, most women interviewed had at least heard about the technology.

Getty Images

News | Mammography | July 15, 2021
July 15, 2021 —  For any type of diagnostic test, technology that helps improve the reliability of test results is a
ujifilm's robust medical systems portfolio includes a comprehensive product lineup covering CT, MRI, fluoroscopy, digital radiography, women’s health, ultrasound, systems integration, endoscopy and endosurgery, enterprise imaging, assisted reproductive technology, cell culture media, cell therapy development, In-Vitro diagnostics (IVD), and investigational drug development
News | Radiology Imaging | July 14, 2021
July 14, 2021 — Fujifilm announced the launch of the ...
A new study set out to learn more about breast health for Black women and to establish a better understanding of the breast screening landscape by analyzing mammograms, screening intervals and interpretation performance for Asian, Black and white women across health systems throughout the United States, with participation from Advocate Health Care, Sanford Health and the University of Pennsylvania Health System.

Getty Images

Feature | Breast Imaging | July 06, 2021 | By Linda Goler Blount, MPH
Due to dangerous implications for years to come, facilities must increase efficiency and capacity for breast cancer care to recover from the impact of COVID-19

Getty Images

Feature | Breast Imaging | July 06, 2021 | By Ananth Ravi, Ph.D.
The challenges